These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 32476520)

  • 21. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
    Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenalidomide: an update on evidence from clinical trials.
    Dimopoulos MA; Terpos E
    Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
    Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
    Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
    Richardson PG; Jagannath S; Moreau P; Jakubowiak AJ; Raab MS; Facon T; Vij R; White D; Reece DE; Benboubker L; Zonder J; Tsao LC; Anderson KC; Bleickardt E; Singhal AK; Lonial S;
    Lancet Haematol; 2015 Dec; 2(12):e516-27. PubMed ID: 26686406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
    Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA
    Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
    Siegel DS; Weisel KC; Dimopoulos MA; Baz R; Richardson P; Delforge M; Song KW; San Miguel JF; Moreau P; Goldschmidt H; Cavo M; Jagannath S; Yu X; Hong K; Sternas L; Zaki M; Palumbo A
    Leuk Lymphoma; 2016 Dec; 57(12):2833-2838. PubMed ID: 27267105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
    Raab MS; Engelhardt M; Blank A; Goldschmidt H; Agis H; Blau IW; Einsele H; Ferstl B; Schub N; Röllig C; Weisel K; Winderlich M; Griese J; Härtle S; Weirather J; Jarutat T; Peschel C; Chatterjee M
    Lancet Haematol; 2020 May; 7(5):e381-e394. PubMed ID: 32171061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
    Eleftherakis-Papapiakovou E; Kastritis E; Roussou M; Gkotzamanidou M; Grapsa I; Psimenou E; Nikitas N; Terpos E; Dimopoulos MA
    Leuk Lymphoma; 2011 Dec; 52(12):2299-303. PubMed ID: 22141916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
    Weisel KC; Dimopoulos MA; Moreau P; Lacy MQ; Song KW; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Knop S; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel J
    Haematologica; 2016 Jul; 101(7):872-8. PubMed ID: 27081177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of myeloma-associated renal dysfunction in the era of novel therapies.
    Gaballa MR; Laubach JP; Schlossman RL; Redman K; Noonan K; Mitsiades CS; Ghobrial IM; Munshi N; Anderson KC; Richardson PG
    Expert Rev Hematol; 2012 Feb; 5(1):51-66; quiz 67-8. PubMed ID: 22272706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
    Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
    Cejalvo MJ; de la Rubia J
    Future Oncol; 2015; 11(11):1643-58. PubMed ID: 25857329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.
    Suzuki K; Ri M; Chou T; Sugiura I; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Ota K; Iida S
    Cancer Sci; 2017 Mar; 108(3):461-468. PubMed ID: 28092421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma.
    Sharpley FA; Djebbari F; Fourali S; Kothari J; Lynes JA; McLain-Smith S; Ramasamy K
    Leuk Lymphoma; 2020 Mar; 61(3):732-736. PubMed ID: 31771382
    [No Abstract]   [Full Text] [Related]  

  • 37. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
    Usmani SZ; Schjesvold F; Oriol A; Karlin L; Cavo M; Rifkin RM; Yimer HA; LeBlanc R; Takezako N; McCroskey RD; Lim ABM; Suzuki K; Kosugi H; Grigoriadis G; Avivi I; Facon T; Jagannath S; Lonial S; Ghori RU; Farooqui MZH; Marinello P; San-Miguel J;
    Lancet Haematol; 2019 Sep; 6(9):e448-e458. PubMed ID: 31327689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current treatments for renal failure due to multiple myeloma.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2016 Nov; 17(16):2165-2177. PubMed ID: 27646819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
    Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.
    Dimopoulos M; Weisel K; van de Donk NWCJ; Ramasamy K; Gamberi B; Streetly M; Offidani M; Bridoux F; de la Rubia J; Mateos MV; Ardizzoia A; Kueenburg E; Collins S; Di Micco A; Rosettani B; Li Y; Bacon P; Sonneveld P
    J Clin Oncol; 2018 Jul; 36(20):2035-2043. PubMed ID: 29394124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.